Investigation of the incidence, severity, and treatment of dabigatran-related dyspepsia symptoms in patients with non-valvular atrial fibrillation (NVAF)

Trial Profile

Investigation of the incidence, severity, and treatment of dabigatran-related dyspepsia symptoms in patients with non-valvular atrial fibrillation (NVAF)

Completed
Phase of Trial: Phase III

Latest Information Update: 16 May 2016

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Antiulcers; Histamine H2 receptor antagonists; Proton pump inhibitors
  • Indications Atrial fibrillation; Dyspepsia; Embolism and thrombosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Apr 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
    • 03 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top